Aravax is a clinical-stage biotechnology company developing the first safe, convenient and disease-modifying treatment for peanut allergy
Microscope
PVX108
PVX108
About Us

Aravax is a clinical-stage biotechnology company developing the first safe, convenient and disease-modifying treatment for peanut allergy.

Aravax uses proprietary platform technology to precisely reset the immune system to tolerate allergens, without provoking severe reactions during treatment

Clinical Trials

Clinical trials AVX-001 and AVX-001-EXT are the first studies of PVX108 to be successfully completed.

Preparations for Phase 2 trials in U.S. and Australia are ongoing, with the trial AVX201 planned to commence in 2022.